Open access
Open access
Powered by Google Translator Translator

Onco-hematology

RCT | Ruxolitinib achieves greater molecular response and EFS in hydroxycarbamide-resistant Polycythemia Vera

22 May, 2023 | 13:35h | UTC

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial – Journal of Clinical Oncology

Commentary: Ruxolitinib Appears to Yields Superior Responses in Polycythemia Vera Subtype – Cancer Network

 


RCT | Superior progression-free survival with Venetoclax-based regimens in first-line CLL treatment

22 May, 2023 | 13:32h | UTC

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: First-Line Venetoclax Combinations vs Chemoimmunotherapy in Fit Patients With CLL – The ASCO Post

 

Commentary on Twitter

 


RCT | The addition of Quizartinib to chemotherapy improves overall survival vs placebo in FLT3-ITD-positive AML patients

18 May, 2023 | 13:40h | UTC

Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)

 

Commentary on Twitter (thread – click for more)

 


Phase 2 RCT | Ropeginterferon shows better results in hematocrit control vs phlebotomy alone in patients withr polycythemia vera

18 May, 2023 | 13:37h | UTC

Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera – NEJM Evidence

 


RCT | Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma

16 May, 2023 | 14:48h | UTC

Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial – Nature Medicine

News Release: Investigational drug may improve stem cell transplantation for multiple myeloma patients – Washington University in St. Louis

 

Commentary on Twitter

 


RCT | Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide for Waldenström’s Macroglobulinemia

16 May, 2023 | 14:24h | UTC

Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström’s Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström’s Macroglobulinemia – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: Addition of Bortezomib to First-Line Dexamethasone, Rituximab, and Cyclophosphamide for Waldenström’s Macroglobulinemia – The ASCO Post

 


Review | Treatment of amyloidosis: present and future

12 May, 2023 | 13:22h | UTC

Treatment of amyloidosis: present and future – European Heart Journal Supplements

See all articles in the series here

 


RCT | Ibrutinib plus rituximab improve CLL PFS vs chemoimmunotherapy, but increased unexplained/cardiac deaths

8 May, 2023 | 13:00h | UTC

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial – The Lancet Oncology

 


Cohort Study | Ibrutinib is associated with increased cardiovascular events and major bleeding in older CLL patients

8 May, 2023 | 12:59h | UTC

Ibrutinib Is Associated With Increased Cardiovascular Events and Major Bleeding in Older CLL Patients – JACC: CardioOncology

 

Commentary on Twitter

 


4 or more CT scans in childhood correlate with elevated cancer risk

4 May, 2023 | 13:59h | UTC

Risks of leukemia, intracranial tumours and lymphomas in childhood and early adulthood after pediatric radiation exposure from computed tomography – Canadian Medical Association Journal

News Release: Single CT scan in kids low risk for cancers, but 4 or more CTs increases risk – Canadian Medical Association Journal

 


RCT | Evaluating subcutaneous rituximab for the first-line treatment of low–tumor burden follicular lymphoma

3 May, 2023 | 15:07h | UTC

Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low–Tumor Burden Follicular Lymphoma: Results of a LYSA Study – Journal of Clinical Oncology (link to abstract – $ for full-text)

 


RCT | Liso-cel, a CAR T-Cell therapy, significantly improves outcomes in large B-Cell lymphoma second-line treatment

2 May, 2023 | 13:28h | UTC

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study – Blood

Commentary: Lisocabtagene Maraleucel Bests Standard Care in LBCL – Cancer Therapy Advisor

 


Single-arm study | Blinatumomab added to chemotherapy in infant lymphoblastic leukemia

28 Apr, 2023 | 13:08h | UTC

Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia – New England Journal of Medicinev (link to abstract – $ for full-text)

News Release: Immunotherapy strongly improves prognosis of babies with leukemia – Princess Máxima Center

 

Commentary on Twitter

 


ASCO Guideline Update | Venous thromboembolism prophylaxis and treatment in patients with cancer

25 Apr, 2023 | 14:49h | UTC

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update – Journal of Clinical Oncology

Commentary: ASCO Updates Guideline on Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer – ASCO Daily News

 


Consensus Paper | Management of pathological thoracolumbar vertebral fractures in patients with multiple myeloma

25 Apr, 2023 | 14:11h | UTC

Management of Pathological Thoracolumbar Vertebral Fractures in Patients With Multiple Myeloma: Multidisciplinary Recommendations – Global Spine Journal

 


Review | Long-term outcomes following CAR T cell therapy: what we know so far

18 Apr, 2023 | 13:12h | UTC

Long-term outcomes following CAR T cell therapy: what we know so far – Nature Reviews Clinical Oncology (if the link is paywalled, try this one in PMC)

 

Commentary on Twitter

 


Guideline | First line treatment of newly diagnosed transplant ineligible multiple myeloma

11 Apr, 2023 | 14:22h | UTC

First Line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Recommendations from the Canadian Myeloma Research Group Consensus Guideline Consortium – Clinical Lymphoma, Myeloma & Leukemia

 


Guidelines on diagnosis and management of chronic neutropenia in adults and children

10 Apr, 2023 | 13:25h | UTC

The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children: A Consensus Between the European Hematology Association and the EuNet-INNOCHRON COST Action – HemaSphere

 

Commentary on Twitter

 


Review | Diagnosis and treatment of chronic lymphocytic leukemia

22 Mar, 2023 | 13:39h | UTC

Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review – JAMA (free for a limited period)

Audio clinical review: Diagnosis and Management of Chronic Lymphocytic Leukemia – JAMA

 


RCT | Overall survival with Daratumumab, Lenalidomide, and Dexamethasone in previously treated multiple myeloma

16 Mar, 2023 | 13:07h | UTC

Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial – Journal of Clinical Oncology

Original Study: Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma – New England Journal of Medicine

 


Primary myelofibrosis | 2023 update on diagnosis, risk-stratification, and management

16 Mar, 2023 | 12:57h | UTC

Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management – American Journal of Hematology

 


Retrospective Cohort | Arrhythmogenic cardiotoxicity associated with contemporary treatments of lymphoproliferative disorders

14 Mar, 2023 | 13:27h | UTC

Arrhythmogenic Cardiotoxicity Associated With Contemporary Treatments of Lymphoproliferative Disorders – Journal of the American Heart Association

 


DNA sequencing may identify an increased risk of relapse in adults with AML prior to hematopoietic cell transplantation

13 Mar, 2023 | 14:47h | UTC

DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant – JAMA (free for a limited period)

News Release: Blood test identifies acute myeloid leukemia patients at greater risk for relapse after bone marrow transplant – National Institutes of Health

Commentary: Blood Test May Identify Patients With AML at Greater Risk of Relapse After Bone Marrow Transplant – The ASCO Post

 

Commentary on Twitter

 


Cohort Study | Personalized progression prediction in patients with MGUS or smouldering multiple myeloma

9 Mar, 2023 | 13:59h | UTC

Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study – The Lancet Haematology

Invited Commentary: The PANGEA model: catching the drift from precursor conditions to myeloma in individual patients – The Lancet Haematology

 

Commentary from the author on Twitter (thread – click for more)

 


RCT | Momelotinib vs. danazol in symptomatic patients with anemia and myelofibrosis

1 Mar, 2023 | 13:39h | UTC

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study – The Lancet (link to abstract – $ for full-text)

News Release: Targeted therapy momelotinib provides significant symptom and anemia improvements in patients with myelofibrosis – University of Texas M. D. Anderson Cancer Center

 


Stay Updated in Your Specialty

No spam, just news.